UNSPSC 51122805: Drobuline

This classification denotes an antiarrhythmic agent with the molecular formula C19H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6LLN8EQ6TA, chemically known as benzenepropanol, alpha-(((1-methylethyl)amino)methyl)-gamma-phenyl-, (+-)- but more generally known as drobuline, which bears US NIH Compound Identifier 60890. European Medicines Agency schedules Drobuline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06401MIG.

UNSPSC 51122805 Drobuline, a Commodity code, covers emergency and critical-care medications supplied to state and local public health agencies, fire departments, and health-benefit programs. Recent solicitations show state and local governments buying life-support injectable medications—epinephrine, labetalol, adenosine, and diltiazem—for emergency medical services and hospital systems, as well as establishing broader pharmaceutical supply channels through cooperative purchasing arrangements. The work ranges from direct medication procurement for specific emergency protocols to participation in multistate generic pharmaceutical networks serving government facilities across regions.

State and local issuing bodies include city fire departments, state health agencies, and cooperative purchasing alliances. The City of Tampa Fire Rescue procured advanced life support medications through an IFB posted April 24, 2026, with a due date of April 8, 2026 and an estimated contract value of $40,000.00, requiring four specific medication line items with nine-month minimum expiration dates and ten-day delivery performance. The Texas Health and Human Services Commission issued a Request for Information in April 2026 exploring direct-to-manufacturer prescription fulfillment capabilities for the state's pharmacy benefit program, signaling intent to restructure pharmaceutical sourcing outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 due March 26, 2026, for generic multi-source pharmaceuticals and over-the-counter products to supply participating state and local facilities across Minnesota and Oregon, with contract effectiveness planned for July 1, 2026. Activity concentrates in Texas, Minnesota, Florida, and Oregon, with solicitations emphasizing compliance with FDA requirements, cGMP and DSCSA certification, OSHA Safety Data Sheets, and WCAG 2.2 accessibility standards where applicable. Small local business enterprise set-asides appear in municipal procurement but not in state-level multistate cooperative vehicles.